TMH study on Covid-19 finds place in WHO’s global literature
The research publication was titled “A Prospective Study on Rapidly Declining SARS-CoV-2 immunoglobulin G (IgG) Antibodies Within 1 to 3 Months of Testing (IgG) Positive: Can It Lead to Potential Reinfections?”
This study paper from TMH-Jamshedpur was recently published in peer-reviewed indexed international journal. The research work is indexed in PubMed, the database for the United States National Library of Medicine.
TATA MAIN HOSPITAL
JAMSHEDPUR: A research study on Covid-19 by Jamshedpur’s Tata Main Hospital (TMH) has made it to World Health Organization’s (WHO’s) global literature on coronavirus disease this year, a statement released by the company said on Saturday.
The research publication was titled “A Prospective Study on Rapidly Declining SARS-CoV-2 immunoglobulin G (IgG) Antibodies Within 1 to 3 Months of Testing (IgG) Positive: Can It Lead to Potential Reinfections?”
“This study paper from TMHJamshedpur was recently published in peer-reviewed indexed international journal. The research work is indexed in PubMed, the database for the United States National Library of Medicine (NLM) at the National Institute of Health. It has now been included in the World Health Organization’s Covid-19 Global literature on coronavirus disease,” the statement said.
“Background Covid-19 immunoglobulin G(IgG) antibodies have been considered to provide protective immunity and its immunoassays have been widely used for sero-surveillance. In our sero-surveillance on an industrial workforce of randomly selected 3,296 subjects, Covid-19 IgG antibody positivity was reported in 7.37% (243) subjects,” the research paper by DS Chaudhry, R Mishra, M Rai and S Gupta stated.
“Thirty days later, eight of the 243 Covid-19 IgG antibody-positive individuals complained of symptoms suggestive of Covid-19 infection and were confirmed as Covid-19 infection by reverse transcription-polymerase chain reaction. When their Covid-19 IgG antibodies were retested, seven of the eight previously IgG positive individuals had lost their protective antibodies,” the study found.
Subsequently, a prospective clinical trial was planned by repeating the test for IgG antibodieson the remaining earlier positive 235 individuals 45-65 days after their initial test. Only 201 of the 235 individuals consented and participated in the non-randomised single-arm observational trial results.